Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.
Overview
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. is a phase 2 interventional study registered as NCT06514534 by Novartis Pharmaceuticals, with 20 participants planned, started 2025-02-18 and due to reach its primary completion in 2029-02-17. Interventions recorded: ABL001/Asciminib.
Similar pages
not linked directly; found by shared links- TrialStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Shares Asciminib, Advanced Accelerator Applications (Novartis), Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.